Publications, Pharmaceutical

Aptar Pharma discusses an antibody nasal spray for SARS-CoV-2

The delivery of antibodies by nasal spray has considerable potential for the treatment of SARS-CoV-2 and other viruses that enter the body via the upper respiratory system.

This paper describes work to develop a novel human antibody nasal spray as a prophylactic treatment against SARS-CoV-2. Formulations were developed at two protein concentrations and assessed for delivery using an Aptar VP3 nasal spray pump. Both formulations were shown to be suitable for nasal delivery in terms of pH, osmolality, and delivered droplet size; no evidence of protein agglomeration was observed as a result of spraying. Further studies are planned to investigate the stability of the developed products and to establish pharmacokinetics and pharmacodynamics.

Download Publication
8 Dec 2021

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More

This Might Also Be of Interest

24 Apr 2024

Advancing OINDP Clinical Trials with Speed and Efficiency: Strategies for Success

Publications, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions

Read More
24 Apr 2024

Exploring Nasal Casts in Nasal Drug Development

Publications, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions

Read More
3 Apr 2024

Delivering Nasally Administered Biologics

Webinars, Pharmaceutical, Product Solutions, Innovation & Insights, Device Innovations, Market Insights

Read More
3 Apr 2024

Nasal Casts, Tools to Enable Nasal Drug Delivery Development

Webinars, Pharmaceutical, Market Insights, Product Solutions, Device Innovations

Read More
1 2 3 25
Back To Top